Takeda records $770M writedown on failed stem cell therapy Alofisel and withdrawn cancer drug Exkivitynews2023-10-26T11:30:33+00:00October 26th, 2023|Endpoints News|
Like Moderna, pandemic peers Pfizer and BioNTech head to PhIII with Covid/flu combo vaccinenews2023-10-26T11:19:26+00:00October 26th, 2023|Endpoints News|
Thermo Fisher grows into CGT manufacturing, while Samsung Biologics expands into ADCsnews2023-10-26T11:13:03+00:00October 26th, 2023|Endpoints News|
Triveni Bio launches with $92M Series A to fund trials for eczema antibody treatmentnews2023-10-26T10:00:25+00:00October 26th, 2023|Endpoints News|
Europe’s Sofinnova raises first $200M digital medicine fund, looking to back over 15 startupsnews2023-10-26T04:00:49+00:00October 26th, 2023|Endpoints News|
Injected form of Leqembi appears effective at clearing amyloid, but with notable risksnews2023-10-26T01:31:56+00:00October 26th, 2023|Endpoints News|
Analyis of Lilly and Eisai’s Alzheimer’s trials suggests early treatment has greater benefitnews2023-10-26T01:13:00+00:00October 26th, 2023|Endpoints News|
ACIP recommends routine use of mpox vaccine for at-risk adults, opening the door to potential 2024 launchnews2023-10-25T19:39:27+00:00October 25th, 2023|Endpoints News|
Remote FDA drug inspections: New draft guidance spells out post-pandemic specificsnews2023-10-25T19:34:33+00:00October 25th, 2023|Endpoints News|
Roche’s sequel to failed Alzheimer’s antibody gantenerumab looks promising in early studynews2023-10-25T19:18:27+00:00October 25th, 2023|Endpoints News|
